ABSTRACT
INTRODUCTION
-Thalassemia and sickle cell disease are among the most common inherited genetic disorders in the world. In -thalassemia, unpaired -globin chains accumulate and precipitate within erythroid cells, resulting in red cell damage, hemolysis, ineffective erythropoiesis and anemia. In sickle cell disease intracellular accumulation of polymerised hemoglobin causes sickling of red blood cells and vascular occlusion.
Amelioration of clinical symptoms associated with these hemoglobinopathies has been reported in patients with elevated levels of -globin chain synthesis. Inthalassemia, the presence of -globin inhibits the precipitation of unpaired -globin through the formation of fetal hemoglobin (HbF , 2 However, a small number of HPFH cases have been identified which are not linked to the -globin locus implicating the presence of trans-acting factor(s).
4-6 Other genetic
conditions that contribute to elevated levels of HbF include metabolic disorders such as propionic acidemia 7 and -ketothiolase deficiency 8 , implicating short chain fatty acids in the induction of HbF. In addition, many acquired conditions have also been A number of published studies have focussed on the development of sensitive assays for HbF inducers utilising various reporters in small plasmid constructs, in combination with some of the regulatory elements from the -globin locus. While some of these assays have yielded interesting results, [19] [20] [21] it is questionable whether the use of globin regulatory elements out of their natural context can recapitulate the requirements for therapeutic HbF reactivation in the erythropoietic compartment.
The usefulness of an assay system for HbF reactivation is critically dependent on the choice of cell line to be used. The human erythroleukemia K562 cell line has been shown to undergo erythroid differentiation and -globin gene expression after treatment with a variety of chemical compounds. 10-18 Importantly, many of these compounds have also been reported to stimulate fetal hemoglobin production in human erythroid precursor cells from normal subjects and in human patients. Murine erythroleukemia cells (MEL) with an adult type of hemoglobin expression have also For personal use only. on November 16, 2017. by guest www.bloodjournal.org From types. We also found that EBACs could be maintained episomally for at least three months in the K562-EBNA1 cell lines under hygromycin selection, while the episomes were lost quickly in MEL-EBNA1 cell lines, (data not shown), presumably due to less specific interaction between mouse chromatin and the EBNA1 protein. To minimise the effect of clonal differences in the measurement of gene expression, pools of hygromycin-resistant cells were used throughout this study. 
Episomal maintenance and expression of EGFP-modified -globin
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In this study, we report the delivery and functional analysis of EBACs containing EGFP-modified -globin locus in human and mouse erythroleukemic cells. The EBAC system incorporates the EBNA1 gene and oriP elements of the Epstein-Barr virus and thus facilitates the maintenance of large genomic fragments as episomes in human cells under hygromycin selection. However, we have found that expression of EBNA1 is not only essential for the episomal maintenance of EBACs, but it also significantly enhances transfection efficiency (Figure 2 ). This effect is particularly marked for larger molecules and is manifested only when EBNA1 is present in the recipient cells prior to transfection. The exact mechanism by which EBNA1 facilitates preferentially transfection of large EBACs is not entirely clear, but it may be related to its known binding to karyopherins. In order to monitor expression of each of the globin genes in the context of theglobin locus, we have used the GET Recombination system 30,37 to create a series of EGFP-modified -globin EBACs (Figure 1 ). Transient transfection studies in K562- 
